Olivier Nsekuye

Mr. Olivier Nsekuye

Rwanda Biomedical Center

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
ONOlivier Nsekuye
Olivier Nsekuye
EREdson Rwagasore
Edson Rwagasore
MMMarie Aime Muhimpundu
Marie Aime Muhimpundu
Ziad El-KhatibZiad El-Khatib
Ziad El-Khatib
Daniel NtabanganyimanaDaniel Ntabanganyimana
Daniel Ntabanganyimana
JOJared Omolo
Jared Omolo
We reported the findings of the first Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) four clusters identified in Rwanda. Case-investigations included contact elicitation, testing, and isolation/quarantine of confirmed cases. Socio-demographic and clinical data on cases and contacts were collected. A confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (PCR) while a contact was any person who had contact with a SARS-CoV-2 confirmed case within 72 h prior, to 14 days after symptom onset; or 14 days before collection of the laboratory-positive sample for asymptomatic cases. High risk contacts were those who had come into unprotected face-to-face contact or had been in a closed environment with a SARS-CoV-2 case for >15 min. Forty cases were reported from four clusters by 22 April 2020, accounting for 61% of locally transmitted cases within six weeks. Clusters A, B, C and D were associated with two nightclubs, one house party, and different families or households living in the same compound (multi-family dwelling). Thirty-six of the 1035 contacts tested were positive (secondary attack rate: 3.5%). Positivity rates were highest among the high-risk contacts compared to low-risk contacts (10% vs. 2.2%). Index cases in three of the clusters were imported through international travelling. Fifteen of the 40 cases (38%) were asymptomatic while 13/25 (52%) and 8/25 (32%) of symptomatic cases had a cough and fever respectively. Gatherings in closed spaces were the main early drivers of transmission. Systematic case-investigations contact tracing and testing likely contributed to the early containment of SARS-CoV-2 in Rwanda.

MNMenelas Nkeshimana
Menelas Nkeshimana
DIDeborah Igiraneza
Deborah Igiraneza
DTDavid Turatsinze
David Turatsinze
ONOtto NIYONSENGA
Otto NIYONSENGA
DADeborah Abimana
Deborah Abimana
SNSabin Nsanzimana
Sabin Nsanzimana
The management of COVID-19 in Rwanda has been dynamic, and the use of COVID-19 therapeutics has gradually been updated based on scientific discoveries. The treatment for COVID-19 remained patient-centered and entirely state-sponsored during the first and second waves. From the time of identification of the index case in March 2020 up to August 2021, three versions of the clinical management guidelines were developed, with the aim of ensuring that the COVID-19 patients treated in Rwanda were receiving care based on the most recent therapeutic discoveries. As the case load increased and imposed imminent heavy burdens on the healthcare system, a smooth transition was made to enable that the asymptomatic and mild COVID-19 cases could continue to be closely observed and managed while they remained in their homes. The care provided to patients requiring facility-based interventions mainly focused on the provision of anti-inflammatory drugs, anticoagulation, broad-spectrum antibiotic therapy, management of hyperglycemia and the provision of therapeutics with a direct antiviral effect such as favipiravir and neutralizing monoclonal antibodies. The time to viral clearance was observed to be shortest among eligible patients treated with neutralizing monoclonal antibodies (bamlanivimab). Moving forward, as we strive to continue detecting COVID-19 cases as early as possible, and promptly initiate supportive interventions, the use of neutralizing monoclonal antibodies constitutes an attractive and cost-effective therapeutic approach. If this approach is used strategically along with other measures in place (i.e., COVID-19 vaccine roll out, etc.), it will enable us to bring this global battle against the COVID-19 pandemic under full control and with a low case fatality rate.

21 June 2024 in Journal of Interventional Epidemiology and Public Health
Verified
Journal Article
Open access
ONOlivier Nsekuye
Olivier Nsekuye
EMEric Matsiko
Eric Matsiko
JNJean Claude Niyoyita
Jean Claude Niyoyita
HUHenri Desire Uwayo
Henri Desire Uwayo
FNFabrice Ndicunguye
Fabrice Ndicunguye
ZEZiad El-Khatib
Ziad El-Khatib
Introduction: Blood transfusion saves human lives, but also it can be a route for Transfusion-transmissible Infections (TTIs) such as Human Immuno-Deficiency Virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Syphilis. TTIs are still a threat to the safety of blood given also the growing magnitude of viral infections (HIV, HBV, and HCV) in the population especially in the Western province of Rwanda. This study aimed to explore the risk factors associated with TTIs among blood donors in the Regional Centre for Blood Transfusion (RCBT) of Karongi, Rwanda. Methods: A secondary data analysis was conducted on cross-sectionally collected data from blood donors collected from 2015 to 2019 in the Regional Centre for Blood Transfusion of Karongi. The key variables for the current analysis were age, gender, residence, blood group, occupation, marital status, and blood donor regularity status and TTIs results reported. We analysed data using Stata version 15 and proportions of TTIs by various characteristics were calculated. Logistic regression was used to identify the factors independently associated with each of the TTIs among blood donors. The significant risk factors were assessed using a P-value of 0.05 and 95% confidence intervals. Results: Among 36,708 donations, the proportion of HBV, HCV, HIV and Syphilis was 1.3%, 0.44%, 0.065% and 0.34% respectively and the overall prevalence of all TTIs was 2.1%. HBV was associated with male gender (AOR: 1.7, 95% CI: 1.4-2.1), age group of 26-35 years (AOR: 1.5, 95% CI: 1.2-1.9), being a new blood donors (AOR:13.2, 95% CI: 8.5-20.6), living in Rusizi District (AOR: 2.5, 95% CI: 1.9-3.3) and being married (AOR: 1.7, 95% CI: 1.2-2.4). HCV was associated with male gender (AOR:1.5, 95% CI: 1.1-2.1), age groups of 26- 35 years (AOR:1.6, 95% CI: 1.1-2.5), 36-45 years (AOR:2.0, 95% CI: 1.2-3.5), 46-55 years (AOR:2.4, 95% CI: 1.2-4.8), 56-65 years (AOR:5.8, 95% CI: 2.4-14.0), being a new blood donors (AOR:4.7, 95% CI: 2.8-7.8), Rusizi District (AOR:2.9, 95% CI: 1.6-5.3), Nyamasheke District (AOR:3.9, 95% CI: 2.1-7.0) and Karongi (AOR:2.6, 95% CI; 1.4-4.8). HIV was related to being new blood donors (AOR:12.1, 95% CI: 1.6-91.0) and living in urban areas (AOR:4.1, 95% CI: 1.2-13.5). Male gender (AOR:1.9, 95% CI: 1.2-2.9) and new blood donors (AOR: 2.3, 95% CI: 1.4-3.6) determined the risk of Syphilis. Conclusion: This study illuminates key risk factors for TTIs in blood donors, emphasizing the importance of improving donor screening and selection processes. Its findings necessitate enhanced health education and continuous monitoring with sensitive testing methods. The results also underscore the need for such measures in similar settings globally for safer blood supply.